Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
Second Sight Medical Products Trading Up 4.6 %
Shares of EYES Stock opened at $2.05 on Thursday. Second Sight Medical Products has a 52 week low of $1.14 and a 52 week high of $4.24. The company's fifty day simple moving average is $2.11 and its two-hundred day simple moving average is $1.69.
Insider Activity
In other news, Director Gregg Williams purchased 387,044 shares of the business's stock in a transaction that occurred on Wednesday, May 18th. The shares were bought at an average cost of $1.66 per share, for a total transaction of $642,493.04. Following the acquisition, the director now owns 10,277,853 shares of the company's stock, valued at approximately $17,061,235.98. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have acquired 636,734 shares of company stock worth $1,163,387. 47.20% of the stock is currently owned by corporate insiders.